化疗合并高压氧治疗中晚期非小细胞肺癌的临床研究

Combined management of chemotherapy and high pressure oxygen in advanced stages(Ⅲ-Ⅳ) of non-small-cell lung cancer

目的 :寻找治疗中晚期非小细胞肺癌具有高效、低毒的方案。方法 :采用随机分组和应用NC方案 (包括国产长春瑞滨、卡铂 )及NC方案合并高压氧治疗中晚期非小细胞肺癌 3 2例 ;按全国抗肿瘤药物疗效评定标准进行评价。同时对全部病例治疗前后静脉取血进行红细胞免疫功能测定。结果 :采用NC方案合并高压氧治疗组有效率 ( 68.75 %)虽高于单用NC方案组 ( 4 3 .75 %) ,但无明显差异 (P >0 .0 5 ) ;NC方案合并高压氧治疗后红细胞免疫功能无明显变化 (P >0 .0 5 ) ,而单纯NC方案治疗后红细胞免疫功能低于治疗前 (P <0 .0 0 1)。结论 :NC方案合并高压氧治疗中晚期非小细胞肺癌疗效虽比单纯NC方案高 ,但无明显差异 ;然而 ,高压氧能减少NC方案的不良反应和免疫抑制 ,提高患者的红细胞免疫功能 。

Objective:To investigate the effective regimen for advanced non small cell lung cancer(NSCLC).Methods:Thirty two patients with advanced(Ⅲ Ⅳ) NSCLC were randomly divided into 2 groups:control group ( n= 16) were treated with NC regimen (vinorelbine plus carboplatin),and treatment group ( n= 16) received combined therapy (NC regimen plus high pressure oxygen).Red blood cell(RBC) immune function was detected in all patients.Results:There was no statistical difference in therapeutic efficacy between two groups(68.75% vs 43.75%, P> 0.05).RBC immune function showed no obvious change in treatment group( P> 0.05),but had dramatic decrease in control group( P< 0.001) after therapy.Conclusion:Although high pressure oxygen cannot improve the therapeutic efficacy of NC regimen in advanced NSCLC,it is able to alleviate the side effect and immunosuppression of NC regimen. [